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Background: There is a dire need for reliable prognostic markers that can guide effective therapeutic intervention in Crohn’s disease (CD). We examined
whether different phenotypes in CD can be classified based on colonic microRNA (miRNA) expression and whether miRNAs have prognostic utility for CD.
Methods: High-throughput sequencing of small and total RNA isolated from colon tissue from patients with CD and controls without Inflammatory
Bowel Disease (non-IBD) was performed. To identify miRNAs associated with specific phenotypes of CD, patients were stratified according to disease
behavior (nonstricturing, nonpenetrating; stricturing; penetrating), and miRNA profiles in each subset were compared with those of the non-IBD group.
Validation assays were performed using quantitative reverse transcription polymerase chain reaction. These miRNAs were further evaluated by
quantitative reverse transcriptase polymerase chain reaction on formalin-fixed, paraffin-embedded tissue (index biopsies) of patients with nonpenetrating
CD at the time of diagnosis that either retained the nonpenetrating phenotype or progressed to penetrating/fistulizing CD.
Results: We found a suite of miRNAs, including miR-31-5p, miR-215, miR-223-3p, miR-196b-5p, and miR-203 that stratify patients with CD
according to disease behavior independent of the effect of inflammation. Furthermore, we also demonstrated that expression levels of miR-215 in index
biopsies of patients with CD might predict the likelihood of progression to penetrating/fistulizing CD. Finally, using a novel statistical simulation
approach applied to colonic RNA-sequencing data for patients with CD and non-IBD controls, we identified miR-31-5p and miR-203 as candidate master
regulators of gene expression profiles associated with CD.
Conclusions: miRNAs may serve as clinically useful prognostic markers guiding initial therapy and identifying patients who would benefit most from
effective intervention.
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C rohn’s disease (CD) results from an aberrant immuneresponse to the enteric microbiota in a genetically susceptible
host. CD susceptibility genes identified through genome-wide asso-
ciation studies highlight mechanistic pathways, including defective
innate immunity. The innate immune system forms the first line of
defense against pathogens and mediates mucosal responses to res-
ident microbiota. Microbial recognition is initiated by pathogen-
associated molecular patterns triggering extracellular receptors
termed toll-like receptors or intracytoplasmic nucleotide-binding
oligomerization domain-containing protein (NOD)-like receptors.
This leads to downstream signaling through pathways regulated
by nuclear factor kappa-B (NFkB), mitogen-activated protein
kinase, and interferons.1
MicroRNAs (miRNAs) are a group of small (;22 nucleo-
tide), noncoding RNAs that regulate gene expression at the post-
transcriptional level.2 They have emerged as key regulators of
a wide variety of biological processes. A number of miRNAs
have already been identified as regulators of pathways that under-
lie the pathogenesis of inflammatory bowel diseases (IBD), which
include CD and ulcerative colitis (UC). For example, miR-192,
miR-122, miR-29, and miR-146a have been shown to target and
repress NOD2, which has been implicated in CD.3–6 Furthermore,
a single nucleotide polymorphism (SNP), rs3135500, in the
3’ UTR of NOD2 weakens the miR-192 target site resulting in
reduced inhibition of NOD2.4 Another miRNA regulator of
NOD2 expression, miR-146a, has been shown to drive interleukin
6 and tumor necrosis factor (TNF) secretion in muramyl dipep-
tide–activated macrophages in experimental models of colitis.5
Recent studies have performed miRNA profiling in tissues
of patients with IBD. Most of these studies used either microarray
platforms7–10 or quantitative reverse transcriptase polymerase
chain reaction (qRT-PCR).11–13 These approaches are informative
but harbor at least 3 major limitations. First, they are limited to
known miRNAs and are therefore not sensitive to functionally
distinct miRNA variants known as isomiRs. Second, they often
cannot adequately distinguish among miRNAs in the same family
that differ by only 1 or 2 nucleotides. Third, microarrays have low
dynamic range, which mitigates the accuracy of differential miR-
NA expression analysis across samples, particularly for more
lowly expressed miRNAs.
Small RNA-sequencing, while not without its own biases,14–16
ameliorates each of these 3 limitations. To our knowledge, only one
study has used this technology to investigate miRNAs in IBD.17 In
our study, we performed next-generation sequencing of small RNAs
isolated from macroscopically noninflamed colon tissue obtained
from a set of extensively phenotyped patients with CD. We stratified
the patients based on inflammatory, stricturing, or penetrating CD
and identified unique colonic miRNA signatures of each class. We
also studied the effect of inflammation on miRNA expression
through small RNA-sequencing of matched colon samples obtained
from macroscopically inflamed regions from a subset of patients with
CD. To determine disease specificity of the inflammation effect, we
used tissue samples from inflamed and noninflamed regions of the
colon in patients with UC as controls. These studies revealed specific
miRNAs that serve as colonic markers of distinct disease behaviors
in CD. Furthermore, we reveal the potential prognostic utility of
miRNAs in CD by demonstrating that miR-215 expression in index
biopsies of well phenotyped patients with nonpenetrating CD ob-
tained at the time of diagnosis may predict progression to penetrating
CD. Finally, using a statistical simulation strategy, we identified




Well-characterized patients with CD from the adult IBD
Center at University of North Carolina were included in this
study. A total of 35 samples were submitted for small RNA- and
RNA-sequencing analyses (see Table, Supplemental Digital
Content 1, http://links.lww.com/IBD/A957). For qRT-PCR vali-
dation, 14 non-IBD (NIBD) controls as well as 21 patients with
SUMMARY BOX
What is known about the subject:
• Crohn’s disease (CD) is a highly variable and complex
disease, which makes diagnosis and effective treatment
a challenge.
• Dysregulated microRNAs (miRNAs) have been iden-
tified in colon and blood plasma of patients with CD
and can be used as biomarkers of disease.
• miRNAs have been shown to regulate specific genes
associated with CD including NOD2, IL-6, and TNF.
What are the new findings:
• miRNA expression profiles stratify distinct behavioral
phenotypes of CD.
• Dysregulated miRNAs, miR-31 and miR-203, are can-
didate master regulators of pathways disrupted in CD
pathogenesis.
• miR-215 is a candidate prognostic indicator of CD
progression.
How might it impact clinical practice in the
foreseeable future:
• Our study shows for the first time that miRNAs are
useful for classification of disease behavior within CD,
which is valuable for determining effective, personal-
ized treatment plans.
• Our findings indicate that specific miRNAs may be
useful in predicting CD progression, which could have
transformative implications for early treatment.
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CD and 6 patients with UC were analyzed (see Table, Supple-
mental Digital Content 2, http://links.lww.com/IBD/A958). In the
prospective study, index biopsies from 10 NIBD control samples,
6 non-B3 patients with CD, and 6 B3 patients were analyzed (see
Table, Supplemental Digital Content 3, http://links.lww.com/IBD/
A959). This study received Institutional Review Board approval
at University of North Carolina (UNC) at Chapel Hill (Protocol
nos. 10-0355 and 15-0024).
Phenotyping
All data were collected by chart review and stored in
a secured database. For the purpose of this study, phenotype was
defined as all variables that were not genetic.
Clinical Phenotype
Clinical phenotypes included demographic and clinical
variables: age, gender, disease duration, age at diagnosis, disease
location, and type of disease behavior (see Tables, Supplemental
Digital Content 4 and 5, http://links.lww.com/IBD/A960 and http://
links.lww.com/IBD/A961) such as B1, nonstricturing and nonpe-
netrating; B2, stricturing; and B3, penetrating/fistulizing. Stricturing
disease was defined as the occurrence of constant luminal narrow-
ing demonstrated by radiologic, endoscopic, or surgical examina-
tion combined with prestenotic dilatation and/or obstructive signs
or symptoms. Penetrating disease was defined as the presence of
perianal, enteroenteric, or enterovesicular fistulae, intra-abdominal
abscesses or intestinal perforation.
Identification of Formalin-fixed,
Paraffin-embedded Sections in Patients
with CD
We identified 12 adult patients followed at the adult IBD
clinic of UNC for inclusion into the study. Each patient was
diagnosed at UNC with formalin-fixed, paraffin-embedded (FFPE)
tissue available from a macroscopically and microscopically
quiescent section of the colon taken at the time of diagnosis (index
biopsy). All 12 patients at time of diagnosis had a B1 CD
phenotype. Six of 12 patients as of 2015 had progressed to a B3
penetrating CD phenotype (5 with perianal fistulizing CD and 2
with intra-abdominal abscess secondary to CD affecting the
terminal ileum). The remaining 6 of the 12 patients remained in
the B1 phenotype (2 of 6 with disease remission and 4 of 6 with
active CD). Mucosal sections were identified by a pathologist (D.G.
T.) from each FFPE sample, and scrolls were obtained to process
for small RNA isolation (see Tables, Supplemental Digital Content
3, http://links.lww.com/IBD/A959 and Figs., Supplemental Digital
Content 6 and 7, http://links.lww.com/IBD/A962 and http://links.
lww.com/IBD/A963). Sections were selected for no or minimal
chronic inflammation. The presence or absence of acute (active)
and chronic inflammation was determined after review of each
H&E stained slide. Activity was determined by the presence of
histologic features of acute inflammation, including neutrophilic
inflammation of crypt epithelium and crypt abscess formation.
Chronicity was determined based on the presence of features such
as architectural distortion and basal lymphoplasmacytosis of the
lamina propria. Degree of activity was determined based on the
percentage of mucosa involved by active inflammation.
RNA Isolation
RNA was isolated from fresh-frozen human colon tissues
using the Qiagen RNeasy Mini Kit (Valencia, CA), which
preserves both miRNA and mRNA content. This kit uses
a column-based DNase treatment to eliminate DNA contamina-
tion. miRNA was enriched from FFPE tissue samples using the
Roche High Pure miRNA Isolation Kit (Penzberg, Germany; see
Fig., Supplemental Digital Content 7, http://links.lww.com/IBD/
A963). RNA purity and integrity were assessed with Thermo
Scientific NanoDrop 2000 (Waltham, MA) and Agilent 2100 Bio-
analyzer (Santa Clara, CA), respectively.
Small RNA- and mRNA-Sequencing and
Expression Analysis
Small RNA libraries were generated using Illumina TruSeq
Small RNA Sample Preparation Kit (San Diego, CA). Single-end
(50 bp) sequencing was performed on the Illumina HiSeq 2500
platform at the UNC High-Throughput Sequencing Facility. Eight
libraries were randomly assigned to each sequencing lane.
miRNAs and their isomiRs were annotated and quantified
according to our previously described bioinformatics analysis
pipeline.14 Sequencing quality and mapping statistics were com-
pared across all samples (see Table, Supplemental Digital Content
8, http://links.lww.com/IBD/A964). miRNAs with an expression
level of 100 reads per million mapped in at least 1 sample were
considered for differential expression analysis.
Libraries for RNA-sequencing were prepared using the
Illumina TruSeq polyA+ Sample Prep Kit. Paired-end (50 bp)
sequencing was performed on the Illumina HiSeq 2500 platform
at the UNC High-Throughput Sequencing Facility. Ten libraries
were assigned to each lane. Genotype data from the Illumina Im-
munochip was available for all samples with RNA-sequencing data.
Genotype imputation was performed with MaCH-admix,18 and cus-
tom genomes were created using genotype calls for all genotyped
and imputed variants. RNA-sequencing reads were then aligned to
personalized genomes using the “SNP-tolerant” GSNAP software.19
This alignment pipeline allows for elimination of mapping biases
that arise from discrepancies in genetic variation between individual
samples and a standard reference genome, at both homozygous
and heterozygous sites. Sequencing quality and mapping statistics
were compared across all samples (see Table, Supplemental
Digital Content 9, http://links.lww.com/IBD/A965). The top 60%
of genes, filtering by the mean of the raw counts, were used for
differential expression analysis. Differentially expressed (DE)
genes in CD samples relative to NIBD samples were identified by
unpaired Student’s t test after variance stabilizing transformation of
the data (DESeq20).
miRNAs and genes were considered significantly DE in CD
relative to NIBD if they had a log2(fold-change [FC]) $61.0 at
a P-value #0.05 by an unpaired 2-tailed Student’s t test. Small
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RNA- and mRNA-sequencing data were deposited in GEO (GEO
accession No. GSE66209).
Quantitative Reverse Transcriptase PCR
Total RNA was isolated from tissues using the Norgen’s
Total RNA Purification kit (Thorold, ON, Canada). Fifty nanograms
of RNA was used for reverse transcription with the Life Technolo-
gies TaqMan MicroRNA Reverse Transcription kit (Grand
Island, NY). miRNA qRT-PCR were performed using the TaqMan
Universal PCR Master Mix per Life Technologies’ protocol, on
a Bio-Rad Laboratories CFX96 Touch Real Time PCR Detection
System (Richmond, CA). Reactions were performed in triplicate
using RNU48 as the normalizer.
miRHub Analysis
Candidate master miRNA regulators were identified by
miRHub,14,21 using the “non-network” mode and requiring
a predicted target site to be conserved between human and at
least one other species.
RESULTS
Small RNA-sequencing Reveals Distinct
miRNA Signatures in the Noninflamed Colon
of Patients with CD with Different
Disease Behaviors
To characterize the small RNA transcriptome in different
phenotypic classes of CD, we performed high-throughput sequenc-
ing of small RNA isolated from noninflamed colon tissue from 21
patients and 14 NIBD controls (Methods). We obtained an average
of approximately 18.5 million reads per sample, of which an
average of approximately 75% were mapped to the human genome
(see Table, Supplemental Digital Content 8, http://links.lww.com/
IBD/A964). Individual miRNAs were annotated and quantified
according to our previously described small RNA-sequencing anal-
ysis pipeline (Methods, GEO accession No. GSE66209). We found
that the expression levels of 4 miRNAs (miR-31-5p, miR-149-5p,
miR-150-5p, and miR-375) were significantly altered (log2(FC) .
1 or , 21, P , 0.05, 2-tailed unpaired Student’s t test) in patients
with CD compared with NIBD controls (Fig. 1A).
To identify miRNAs associated with specific CD pheno-
types, we stratified the 21 patients according to their disease
subclass (B1: nonstricturing and nonpenetrating, n ¼ 8; B2: stric-
turing, n ¼ 6; and B3: penetrating, n ¼ 7) and compared miRNA
profiles in each class with those of the NIBD control group. We
found 9, 6, and 9 significantly (log2(FC) . 1 or , 21, P , 0.05)
DE miRNAs in the B1, B2, and B3 classes, respectively (Fig. 1B–
D; see Table, Supplemental Digital Content 10, http://links.lww.
com/IBD/A966). These included several 5’-end variants of canon-
ical miRNAs (referred to as 5’-isomiRs), such as miR-375-3p+1,
miR-143-3p-1, and miR-378a-3p+1, which have been shown to
be functionally relevant and are only distinguishable from their
canonical counterparts by sequencing-based analysis.14,22,23
Strikingly, we found that the majority of the significantly DE
miRNAs in each disease class were unique to that class (Fig. 1).
Specifically, 9/9, 4/6, and 7/9 miRNAs were exclusively DE com-
pared with NIBD controls in B1, B2, and B3, respectively (Fig.
1E). For example, miR-150-5p, which normally represses the
immune response,24 was significantly downregulated only in the
B1 disease class (see Fig., Supplemental Digital Content 11,
http://links.lww.com/IBD/A967). Also, miR-31-5p (up), miR-149-
5p (down), miR-196b-5p (down), miR-215 (up), miR-223-3p (up),
FIGURE 1. Scatter plots showing average miRNA expression as determined by small RNA-sequencing comparing (A) CD, (B) B2/nonstricturing,
nonpenetrating class, (C) B2/stricturing class, and (D) B3/penetrating class with NIBD patient samples. (E), Venn diagram showing overlap of
significantly DE microRNAs relative to NIBD. Gray shaded region indicates log2(FC) , 1 or . 21. Size of point indicates significance level as
determined by a 2-tailed unpaired Student’s t test, whereas color indicates direction of change. miRNAs achieving significance and log2(FC) of. 1
or , 21 change in expression are labeled and considered DE.
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and miR-203 (down) were altered in B2 and/or B3, both of which
exhibit fibrosis and penetrating/fistulizing phenotypes, but not in
B1 (Fig. 2). The downregulation of miR-196 (Ref. 25) and
miR-203,26 as well as the upregulation of miR-192/215 (Ref. 27)
and miR-223 (Ref. 28) have been associated with fibrosis in dif-
ferent tissues including kidney and skin. miR-31-5p and miR-149-
5p were significantly DE in both B2 and B3 classes (Fig. 2A, G).
Although ileocolonic miR-31 levels were previously associated
with CD,29,30 miR-149-5p has only been reported previously as
a plasma marker of CD.8,31
To validate these findings, we performed qRT-PCR (Meth-
ods) for 3 miRNAs (miR-31-5p, miR-215, and miR-149-5p).
We confirmed that all 3 were unchanged in B1 but DE in both
B2 and B3 (Fig. 3). miR-31-5p was the most prominently upregu-
lated in both B2 (7.6-fold) and B3 (9.2-fold), whereas miR-215 was
more modestly upregulated in B3 (1.7-fold), and miR-149-5p was
significantly downregulated in both B2 (23.6-fold) and B3
(22.6-fold).
Taken together, these results reveal distinct miRNA
signatures associated with different CD disease classes. In
particular, patients with B2/stricturing and/or B3/penetrating
phenotypes exhibit a completely different colonic miRNA profile
than patients without either of those conditions. To our knowl-
edge, these findings are the first to demonstrate that molecular
subtypes of CD stratify according to miRNA profiles.
Inflammation Is Not a Primary Driver of
miR-31-5p, miR-215, and Other
CD-associated miRNAs
To determine whether the DE miRNAs are further dysregu-
lated by active inflammation, we performed small RNA-sequencing
on total RNA isolated from inflamed colon tissue from 6
individuals with CD, including at least 1 from each disease
class (B1, n ¼ 3; B2, n ¼ 1; B3, n ¼ 2), and compared the
miRNA profiles with those of the patient-matched noninflamed
tissue (see Fig. A and B, Supplemental Digital Content 12,
http://links.lww.com/IBD/A968; Table, Supplemental Digital
Content 8, http://links.lww.com/IBD/A964, GEO accession
No. GSE66209). We found that none of the 22 miRNAs that
were found to be significantly DE in the noninflamed colon of
B1, B2, or B3 classes of patients with CD (Fig. 1) were signif-
icantly altered in the matched inflamed tissue (Fig. 4; see Fig. A,
C and D, Supplemental Digital Content 12, http://links.lww.
com/IBD/A968), although miR-149-5p did trend upward
(Fig. 4E). As a positive control, we compared miR-132 and
miR-99b-5p, both of which are known to be associated with
proinflammatory processes32,33 and found that they were indeed
significantly elevated in inflamed relative to noninflamed
colon tissue (see Fig. E and F, Supplemental Digital Content
12, http://links.lww.com/IBD/A968). These findings suggest
FIGURE 3. Relative miRNA expression levels (22DCt) as determined by
qRT-PCR and normalized to RNU48 are shown for (A) miR-31-5p, (B)
miR-215, and (C) miR-149-5p in NIBD (n ¼ 15, gray) and CD (n ¼ 20,
black) patient samples. CD samples are further categorized as B1
(purple, n ¼ 7), B2 (pink, n ¼ 6), or B3 (orange, n ¼ 7). Mean and SE for
each group are depicted using horizontal and vertical bars. Signifi-
cance is determined using a 2-tailed unpaired Student’s t test com-
paring each group with NIBD samples. *P , 0.05, **P , 0.01.
FIGURE 2. miRNA expression (reads per million mapped) as deter-
mined by small RNA-sequencing is shown for (A) miR-31-5p, (B) miR-
196b-5p, (C) miR-215, (D) miR-223-3p, (E) miR-203, and (F) miR-149-5p
in NIBD (gray, n ¼ 14) and CD (black, n ¼ 21) patient samples. CD
samples are further categorized as B1 (purple, n ¼ 8), B2 (pink, n ¼ 6),
or B3 (orange, n ¼ 7). Mean and SE for each group are depicted using
horizontal and vertical bars. Significance is determined using a 2-tailed
unpaired Student’s t test comparing each group with NIBD samples.
*P , 0.05, **P , 0.01, ***P , 0.001.
Peck et al Inflamm Bowel Dis  Volume 21, Number 9, September 2015
2182 | www.ibdjournal.org
that the CD-associated miRNAs we have identified are molecu-
lar markers of genetic predisposition to CD as opposed to in-
dicators of an acute inflammatory process.
We measured miR-31-5p by qRT-PCR in colon tissue with
low-grade inflammation from patients with UC (n ¼ 6) and found
that the levels were not changed compared with colon tissue from
normal controls (n ¼ 15) (Fig. 4G). Interestingly, miR-31-5p was
4.2-fold elevated in UC patient-matched inflamed tissue (Fig.
4G), unlike what we observed in CD (Fig. 4A).
Taken together, these findings indicate that although
inflammation may modulate miR-31-5p in some disease contexts
such as psoriasis34 or even within the IBDs (UC; Fig. 4G), bio-
logical processes other than inflammation are primarily responsi-
ble for the dysregulation of colonic miRNAs, such as miR-31-5p,
miR-215, and miR-196b-5p, in CD.
miR-215 Is a Potential Predictor of
a Penetrating Disease Phenotype in CD
To determine whether miR-31-5p, miR-149-5p, and miR-
215 could predict the progression of a B1 CD phenotype to a B3
phenotype, we obtained from 12 patients FFPE colon tissue that
was available from biopsies taken at the time of diagnosis at the
UNC Hospital. All twelve patients were classified as B1-type CD
at the time of diagnosis. Six of the 12 patients subsequently
developed a B3 phenotype (B1 / B3), whereas the remaining 6
did not (B1 / non-B3). We performed qRT-PCR (Methods) for
3 miRNAs (miR-31-5p, miR-215, and miR-149-5p) on small
RNAs enriched from the FFPE tissue. There was no statistical
difference in expression of the miRNAs between the 2 groups
(see Fig. 5A and Fig. A and B, Supplemental Digital Content
13, http://links.lww.com/IBD/A969). However, a post hoc analy-
sis revealed that 2 of the patients (both in the B1 / non-B3
group) were in complete clinical and mucosal remission, whereas
the remainder had active disease. Adjusting for these 2 patients,
we found that miR-215 was 4.8-fold enriched in the B1 / B3
group of patients relative to B1 / non-B3 (P ¼ 0.049, by one-
tailed, unpaired, and unequal variance Student’s t Test; Fig. 5B).
To our knowledge, this is the first description of using miRNAs to
prospectively predict disease phenotype in CD.
Whole Transcriptome Analysis Reveals that
miR-31-5p and miR-203 are Candidate Drivers
of the Colonic Gene Expression Profile in CD
To determine whether any of the miRNA markers of CD are
also candidate master regulators of gene networks underlying
disease pathogenesis, we first performed paired-end high-through-
put sequencing of messenger RNAs isolated from the same colon
tissue samples that were used for small RNA-sequencing studies
(Methods). We obtained an average of approximately 29.4 million
paired-end reads per sample, of which an average of approximately
70% mapped uniquely to the human genome (see Table,
FIGURE 4. miRNA expression (reads per million mapped) as deter-
mined by small RNA-sequencing is shown for (A) miR-31-5p, (B) miR-
196b-5p, (C) miR-215, (D) miR-223-3p, (E) miR-149-5p, and (F) miR-203
in 6 matched noninflamed (NI; gray) and inflamed CD samples (IF;
black) patient samples. (G), Relative miR-31-5p expression levels
(22DCt) as determined by qRT-PCR and normalized to RNU48 are
shown for samples from NIBD patients (n ¼ 15), matched NI and IF
patients with CD (n ¼ 19), and matched NI and IF UC patient samples
(n ¼ 6). Significance is determined using a 2-tailed unpaired Student’s
t test comparing each group with NIBD (blue with bar) samples or
matched noninflamed tissue (red with bar). *P , 0.05. Significance
was not achieved by a 2-tailed paired Student’s t test comparing NI
with IF in panels (A–F).
FIGURE 5. Relative miR-215 expression levels (22DCt) as determined by
qRT-PCR and normalized to RNU48 for B1 patient samples that (A)
either progressed to a non-B3/penetrating disease (B1 / non-B3,
n ¼ 6, black) or progressed to B3/penetrating disease (B1/ B3, n ¼ 6,
gray). B, Samples from (B) were subcategorized to include only B1
samples from patients with active CD that did not progress to
B3/penetrating disease (B1 / non-B3, n ¼ 4) or progressed to
B3/penetrating disease (n ¼ 6). Mean and SE for each group are
depicted using horizontal and vertical bars. Significance determined
using a one-tailed, unpaired, and unequal variance Student’s t test
comparing each group with B1 / non-B3 samples. *P , 0.05.
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Supplemental Digital Content 9, http://links.lww.com/IBD/A965).
We used DESeq20 to identify DE genes in CD and in each of B1,
B2, and B3 phenotype classes, relative to the NIBD control group
(Fig. 6A, B). Similar to the results of the small RNA-sequencing
analyses, there was very minimal overlap of DE genes between
pairwise comparisons of B1, B2, and B3 classes (Fig. 6A, B).
These findings highlight the unique molecular identities of different
disease behaviors of CD.
We next applied the miRHub algorithm,14,21 which deter-
mines whether the predicted regulatory effect of any miRNA on
a set of DE genes is significantly greater than expected by
chance (empirical P , 0.05). Only 1 significantly upregulated
miRNA, miR-31-5p, was identified as a candidate master regu-
lator of genes that are downregulated in CD (Fig. 6C). Likewise,
only 1 significantly downregulated miRNA, miR-203, was iden-
tified as a candidate master regulator of genes that are upregu-
lated in CD (Fig. 6).
DISCUSSION
There is a rapidly expanding interest in evaluating the use
of miRNAs as potential diagnostic markers of IBD. Most studies
of miRNA expression in IBD have used qRT-PCR or microarrays
to quantify miRNA abundance. Notable among these was the
demonstration that miRNAs were DE in the sigmoid colons of
patients with UC.7 A subsequent study demonstrated that none of
the CD-associated miRNAs were altered in colon tissues from
patients with UC. Furthermore, miRNA expression in CD limited
to the ileum was different than CD involving the colon.8 Inflam-
mation was shown to alter the profiles of many of the implicated
miRNAs, suggesting inflammation-dependent effects on miRNA
expression. Our study is different in its unbiased, next-generation
sequencing–based approach to small RNAs. To our knowledge,
only 1 study has used small RNA-sequencing in patients with
IBD.30 This study, consistent with our findings, reported that
miR-31 expression was increased in colon tissue from patients
FIGURE 6. Venn diagram showing the number of DE genes (P , 0.05) that were (A) upregulated or (B) downregulated compared with NIBD
controls in each of the CD subclasses. Genes that were significantly upregulated or downregulated in all 3 classes, respectively, are shown on the
right in the bracketed table. C, Enrichment analysis for target sites of expressed miRNAs (reads per million mapped .100) in DE genes as
determined by RNA-sequencing. On the x-axis, DE gene lists were divided into upregulated and downregulated genes for 4 comparisons: CD
versus NIBD, B1 versus NIBD, B2 versus NIBD, or B3 versus NIBD. P-values ,0.05 are shown in shades of red.
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with CD. Although Lin et al used tissues from patients with
ischemic colitis and infectious colitis as controls, the effect of
inflammation in the context of CD on miR-31 expression was
not studied. miR-149 expression was found to be decreased in
peripheral blood in patients with CD, but again, the effects of
active CD versus inactive disease were not studied, making it
difficult to interpret whether plasma miR-149 was truly a marker
of genetic predisposition or a sequela of the inflammatory
response. Using matched inflamed tissue from the same CD
patients, we show that select groups of miRNAs, including
miR-31, are aberrantly expressed in an inflammation-
independent fashion in patients with CD. This effect was not
seen in the inflammatory tissue obtained from patients with
UC, suggesting the potential for the use of miR-31 as a marker
of genetic predisposition for CD.
Perhaps most notably, our study is the first to demonstrate
that miRNAs classify different disease behaviors of CD. We
identify a unique colonic miRNA profile for CD that is character-
ized by a penetrating (fistulas, perianal, and intra-abdominal
abscesses) inflammatory phenotype compared with a nonpenetrating
phenotype. Closer examination of the miRNAs uniquely altered in
each disease behavior revealed pertinent altered biology in CD. For
example, we found that miR-29c was uniquely downregulated in
the B2 class, which is associated with stricturing secondary to
fibrosis. The miR-29 miRNAs have long been established as potent
repressors of fibrosis. The downregulation of miR-29c in B2 is
consistent with the elevation in B2 of several extracellular matrix
genes, including COL6A1, COL6A3, COL21A1, and ELN. In fact,
ELN is a validated target of miR-29 in several different cell
types.35,36 The downregulation of miR-29c in B2 likely leads to
the increased expression of extracellular matrix genes, thereby con-
tributing to the fibrotic phenotype. Also, miR-203 has been shown
to regulate TNF-a, the major biological target in managing patients
with CD.37 In our study, we found miR-203 to be downregulated in
all classes of CD, but only significantly in the B2 class, which may
contribute to elevated TNF-a levels seen in CD.38 Importantly, we
found that the degree of inflammation did not affect the expression
of miR-203.
Our findings highlight the exciting potential of using an
miRNA signature as a disease biomarker. Olaru et al found that
miR-224 and miR-31 were increased successively at each stage
of IBD progression from noninflamed to inflamed nonneoplastic,
dysplastic, and finally cancer.29,39 Zhang et al40 found miR-31 to
be dysregulated in IBD but not microscopic colitis. miR-21 is
also widely reported as dysregulated in UC and CD. Specifi-
cally, Ludwig et al41 found that miR-21 was upregulated in
IBD-associated dysplastic lesions compared with active patients
with IBD. In our study, although highly expressed, there was no
statistical difference in miR-21 expression between NIBD and
CD tissue. These differences may be related to use of colonic
tissue for our study compared with ileal mucosal samples as
previously reported.8,10 However, subgroup analysis based on
disease behavior did reveal that there is a trend toward higher
miR-21 expression in B3 versus NIBD (FC ¼ 4.99, P ¼ 0.14)
that is not seen in B2 (FC ¼ 1) or B1 (FC ¼ 1.2) versus NIBD.
This highlights the importance of studying different disease clas-
ses of CD independently. Future studies similar to ours but
incorporating a larger patient cohort will help to make these
molecular distinctions more evident. Other than miR-31, we
did not see significant changes in colonic expression between
patients with CD and NIBD controls for miRNAs most fre-
quently associated with UC, such as miR-126.10
Our results reveal the importance of accounting for CD
disease behavior in experimental design and data analysis to more
sensitively capture potential diagnostic markers and therapeutic
targets. Previous studies have been inconsistent in identifying
miRNAs that may serve as biomarkers. Furthermore, no attempt
has been made to use an miRNA signature as a potential
prognostic marker of CD. By focusing on miRNAs that are
highly expressed and demonstrate differences based on disease
behavior, we have identified miRNAs with potential diagnostic
and prognostic utility. miR-31 expression levels are similar
between normal mucosal specimens from cecum, ascending,
transverse, descending, sigmoid colon, and rectum, making it
a practical choice as a marker, given the frequency of colonos-
copies and flexible sigmoidoscopes in patients with IBD.29
Our study focused on miRNA expression in the colon.
Signatures in the small bowel are likely different and may add
to the value of our study, particularly because it has been
shown that inflammation does affect miRNA expression in the
ileum.42 miRNAs that we found to be associated with a pene-
trating phenotype of CD (B3), including miR-31 and miR-215,
are known to be increased in the terminal ileum compared with
the colon.8 A future study design with samples also obtained
from the ileum, incorporating a larger number of patients, may
be able to pinpoint which miRNAs are associated with pene-
trating/fibrosing disease in the small intestine compared with
perianal fistulizing disease in the colon.
Perhaps, the most novel aspect of our study is the use of
a new “prospective” patient cohort. By carefully selecting a group
of patients with penetrating CD who on initial presentation
lacked the presence of penetrating CD, we are able to identify
an miRNA that may be predictive of this disease phenotype.
Furthermore, the ability to test this in an FFPE sample block
makes the application of our work a practical reality with poten-
tial for clinical use. Given the limitations of clinically phenotyp-
ing patients with CD, there is a need to develop molecular
phenotypes that help to predict disease behavior. There are many
inherent difficulties in patient selection when conducting a pro-
spective biomarker study, including availability of tissue at the
time of disease diagnosis, availability of detailed and careful
phenotyping of patient disease course, clinical follow-up, and
accurate technology for analysis of FFPE samples. Given these
challenges, our sample numbers are small, but the study has
nonetheless yielded novel and intriguing results, which merit
detailed further investigation. Interestingly, post hoc analysis of
the B1 / B3 group showed that miR-215 was most increased in
patients with a penetrating CD phenotype of the ileum (see
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Fig., Supplemental Digital Content 14, http://links.lww.com/IBD/
A970) compared with the patients with perianal fistulizing CD.
Given the recent study showing that peripheral blood miRNAs
can be used to distinguish active CD and UC from healthy controls,
it will be interesting to test the potential of the select group of
miRNAs that share a common systemic and colonic expression
profile. Our findings demonstrate that miRNAs can be used to
classify different CD disease behaviors and lay the groundwork
to study their clinical utility as prognostic markers of IBD.
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